About
Cancer Drug Discovery Using Bi-specific Antibodies
Fusimabs platform is based on inclonal technology developed by Professor Itai Benhar at the University of Tel-Aviv. It is designed to enable the efficient expression and folding of full-length antibodies in bacterial culture. Fusimab is leveraging its platform for development of bi-specific antibodies and antibody toxin fusion proteins for cancer treatment.The technology may offer a way to speed up drug discovery and manufacturing.
Identity
| Name | Fusimab |
|---|---|
| Slug | fusimab |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7sp9cKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2014 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | HaNehoshet Street 4, Tel Aviv-Yafo, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Tags
antibodiespharmaceuticalsbiotechnologycancerbacteriapharma-companiestreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}